C-erbB-2过度表达对乳腺癌术后化疗选择的影响

被引：6

作者：

唐发宝

夏勇

机构：

[1] 南昌市第三医院乳腺疾病研究所药学研究室

来源：

中华普通外科杂志 | 2006年 / 12期

关键词：

过度表达; CMF; 化疗方案; 乳腺癌患者; C-erbB-2;

D O I：

暂无

中图分类号：

R737.9 [乳腺肿瘤];

学科分类号：

100214 ;

摘要：

<正>C-erbB-2为人类原癌基因,也称HER-2／neu,位于第17对染色体长臂21位(17q21),编码1255个具有跨膜酪氨酸激酶活性的生长因子受体,是表皮生长因子受体家族成员之一,分子量约为185 kD,因此又被称为p185。C-erbB-2在正常组织中不表达或微量表达,人类肿瘤组织如乳腺癌、卵巢癌、子宫内膜癌、输卵管癌、宫颈癌、前列腺癌、胃癌、唾液腺癌、舌癌、头颈部鳞癌、非小细胞性肺癌,C-erbB-2过度表达的约30％。临床评估C-erbB-2表达状态,主要通过免疫组化法(IHC)和原位荧光原位杂交法(FISH),IHC检测为C-erbB-2(+++)或IHC检测为C-erbB-2(++)／FISH检测为(+)者,确定为C-erbB-2过度表达。C-erbB-2是乳腺癌重要的分子生物学标记,其表达过度与否不仅在乳腺癌发生、发展、转移和预后中起重要作用,对乳腺癌的化疗也具有十分重要的临床参考价值。

引用

页码：901 / 902

页数：2

共 11 条

[1]

C-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Stal O,,Sullivan S,Wingren S, et al. European Journal of Cancer . 1995

[2]

Overexpression of ErbB2 blocks taxol-induced apoptosis by upregulation of p21 Cipl, which inhibits p34 Cdc2 kinase. Yu D,Jing T,Liu B, et al. Molecular Cell . 1998

[3]

Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 over-expression and other tumor biologic variables. Menard S,Valagussa P,,Pilotti S, et al. Journal of Clinical Oncology . 2001

[4]

Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel ( Taxol) by adenovirus type 5 E1A. Ueno NT,Yu D,Hung MC. Oncegene . 1997

[5]

Resistance to taxanes is induced by C-erbB-2 overexpressing in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A. Ciardiello F,Caputo R,Poroatico G, et al. International Journal of Cancer . 2000

[6]

C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. Muss HB,Thor AD,Berry DA, et al. The New England Journal of Medicine . 1994

[7]

Overexpression of HER2 modulates Bel-2,Bel-XL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells. Kumar R,Mandal M,Lipton A, et al. J Clin Cancer Res . 1996

[8]

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. Seidman AD,Founier MN,Esteva FJ, et al. Journal of Clinical Oncology . 2001

[9]

Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/ fluorouracil. Miles DW,Harris WH,Gillett CE, et aL. International Journal of Cancer . 1999

[10]

Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. Petit T,Borel C,Ghnassia JP, et al. Clinical Cancer Research . 2001

← 1 2 →